CorpusHuman Anatomy

Cytotoxic T cell (CD8⁺)

Also known as: CD8 T cell, CD8+ T cell, CTL, cytotoxic T lymphocyte, killer T cell, Tc cell

CD8⁺ T cells that recognise foreign peptides presented on MHC class I — which every nucleated cell displays — and kill virus-infected, tumour and foreign cells by inducing apoptosis with perforin and granzymes.

Adaptive Immune Response

Overview

Because almost every nucleated cell expresses MHC class I and continually displays fragments of its own cytosolic proteins on it, CD8 T cells can detect infection or malignancy in any tissue. A naive CD8 T cell is primed in a lymph node by a dendritic cell — either one infected by the virus or one that has cross-presented antigen from an engulfed infected cell — usually with CD4 help, which "licenses" the DC through CD40L–CD40 and supplies IL-2. It then proliferates and differentiates into an effector cytotoxic T lymphocyte (CTL) loaded with cytotoxic granules and migrates to the infected tissue.

When a CTL's TCR engages the right peptide–MHC I complex on a target, it forms a tight immunological synapse and secretes the contents of its granules directly onto the target: perforin polymerises to form pores in the target membrane, allowing granzymes (serine proteases) to enter and activate caspases, triggering apoptosis. CTLs also kill through Fas ligand binding Fas (CD95) on the target, and secrete IFN-γ and TNF-α, which inhibit viral replication and upregulate MHC expression. Apoptosis dismantles the target cell from within, destroying viral replication machinery without spilling virus or causing inflammation. Each CTL detaches unharmed and can kill many targets in succession (serial killing).

Location

Lymph-node paracortex, splenic PALS, blood (≈ 20–30% of lymphocytes) and infected or inflamed tissues; tissue-resident memory CD8 cells in barrier tissues.

Function

  • Kill virus-infected cells and cells infected with other intracellular pathogens.
  • Kill tumour cells presenting mutated or abnormally expressed proteins (tumour immunosurveillance).
  • Kill allogeneic cells (transplant rejection) and, in disease, healthy self cells (autoimmunity).
  • Secrete IFN-γ and TNF-α to inhibit pathogen replication.

Clinical significance

Immunopathology

CTLs cause much of the liver damage in hepatitis B (killing infected hepatocytes), destroy β cells in type 1 diabetes, mediate acute cellular transplant rejection and drive severe cutaneous drug reactions (Stevens–Johnson syndrome/TEN — strongly associated with HLA-B15:02 and carbamazepine in South-East Asian populations; abacavir hypersensitivity with HLA-B57:01).

Tumour immunity and immune evasion

Tumours and viruses evade CTLs by down-regulating MHC class I (which then exposes them to NK cells) or by engaging the inhibitory receptor PD-1 on chronically stimulated, "exhausted" CTLs. Checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) restore CTL activity in melanoma, lung cancer and other cancers.

Compiled from standard anatomy and physiology references — see the Lymphatic & Immune System sources. For education only; not medical advice.